Researchers from the Institute for Bioengineering of Catalonia (IBEC) and collaborators have successfully treated bladder tumors in mice using urease-powered nanobots. The testing consisted of the administration of 18F-nanorobots to tumor-bearing mice divided into four groups depending on tumor volumes using a group of non-tumor-bearing mice as control. Importantly, the therapy remained in the bladder with only a very small proportion of radioactivity seen in other organs. The results were published in Nature Nanotechnology on Jan. 15, 2024.
Genedit Inc. has entered into a multiyear collaboration and license agreement with Genentech Inc., a member of the Roche Group, to use Genedit's Nanogalaxy platform to discover and develop novel hydrophilic nanoparticles to deliver Genentech's nucleic acid-based medicines for treatment of autoimmune disease.
Researchers from Broad Institute and Harvard University presented the discovery of all-in-one virus-like particles (VLPs) designed to deliver prime editor (PE) ribonucleoprotein (RNP) complexes into mammalian cells.
